Institutional Investors Are Dumping Biotelemetry Inc (NASDAQ:BEAT)

BioTelemetry, Inc. (NASDAQ:BEAT) Logo

Sentiment for Biotelemetry Inc (NASDAQ:BEAT)

Biotelemetry Inc (NASDAQ:BEAT) institutional sentiment decreased to 1.13 in 2019 Q1. Its down -0.26, from 1.39 in 2018Q4. The ratio is negative, as 136 investment professionals increased and started new positions, while 120 reduced and sold equity positions in Biotelemetry Inc. The investment professionals in our partner’s database now possess: 29.50 million shares, down from 29.71 million shares in 2018Q4. Also, the number of investment professionals holding Biotelemetry Inc in their top 10 positions decreased from 6 to 4 for a decrease of 2. Sold All: 26 Reduced: 94 Increased: 78 New Position: 58.

BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The company has market cap of $1.64 billion. The firm operates in three divisions: Healthcare, Research, and Technology. It has a 35.96 P/E ratio. The Healthcare segment focuses on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders.

The stock increased 0.90% or $0.43 during the last trading session, reaching $48.44. About 273,478 shares traded. BioTelemetry, Inc. (NASDAQ:BEAT) has risen 24.78% since July 14, 2018 and is uptrending. It has outperformed by 20.35% the S&P500.

Analysts await BioTelemetry, Inc. (NASDAQ:BEAT) to report earnings on July, 24. They expect $0.45 earnings per share, down 2.17 % or $0.01 from last year’s $0.46 per share. BEAT’s profit will be $15.21M for 26.91 P/E if the $0.45 EPS becomes a reality. After $0.42 actual earnings per share reported by BioTelemetry, Inc. for the previous quarter, Wall Street now forecasts 7.14 % EPS growth.

Domini Impact Investments Llc holds 3.79% of its portfolio in BioTelemetry, Inc. for 3,952 shares. 1492 Capital Management Llc owns 63,630 shares or 3.37% of their US portfolio. Moreover, Hood River Capital Management Llc has 3.01% invested in the company for 954,906 shares. The California-based Lyon Street Capital Llc has invested 2.86% in the stock. Crosspoint Capital Strategies Llc, a California-based fund reported 19,785 shares.

BioTelemetry, Inc. (NASDAQ:BEAT) Ratings Coverage

Ratings analysis reveals 100% of BioTelemetry’s analysts are positive. Out of 2 Wall Street analysts rating BioTelemetry, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $80 while the high is $90. The stock’s average target of $85 is 75.47% above today’s ($48.44) share price. BEAT was included in 2 notes of analysts from February 22, 2019. Lake Street maintained it with “Buy” rating and $90 target in Friday, February 22 report. The stock of BioTelemetry, Inc. (NASDAQ:BEAT) earned “Buy” rating by SunTrust on Monday, March 18.

More notable recent BioTelemetry, Inc. (NASDAQ:BEAT) news were published by: Nasdaq.com which released: “Finisar (FNSR) Q4 Earnings Beat Estimates, Revenues Miss – Nasdaq” on June 14, 2019, also Nasdaq.com with their article: “Adobe beats quarterly estimates on cloud strength; shares rise – Nasdaq” published on June 18, 2019, Nasdaq.com published: “Why iRobot (IRBT) Could Beat Earnings Estimates Again – Nasdaq” on July 02, 2019. More interesting news about BioTelemetry, Inc. (NASDAQ:BEAT) were released by: Nasdaq.com and their article: “DAT: Truckload Rates Heat Up in June, as Spot Market Volumes Beat 2018 Levels – Nasdaq” published on July 12, 2019 as well as Nasdaq.com‘s news article titled: “General Mills (GIS) Q4 Earnings Beat Estimates, Sales Up Y/Y – Nasdaq” with publication date: June 26, 2019.

BioTelemetry, Inc. (NASDAQ:BEAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.